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Small-Diameter PTFE Portosystemic Shunts"
Portocaval vs Mesocaval
ABSTRACT
Paquet, K.-J., Lazar, A., Koussouris, P., Hotzel, B., Gad,
H. A., Kuhn, R. and Kalk, J.-F. (1997) Mesocaval
interposition shunt with small-diameter polytetrafluoro-
ethylene grafts in sclerotherapy failure, British Journal of
Surgery; 82, 199-203.
Fifty-seven patients with failed sclerotherapy re-
ceived a mesocaval interposition shunt with an
externally supported, ringed polytetrafluoroethylene
prosthesis of either 10 or 12mm diameter. Thirty-one
patientshad Child-Pugh gradeA disease and 26 grade
B; all had a liver volume of 1000-2500 ml. Follow-up
ranged from 16 months to 6 years 3 months. Three
patients (5 per cent) died in the postoperative period.
There were two postoperative recurrences of variceal
haemorrhage and one recurrent bleed in the second
year after surgery. The cumulative shunt patency rate
was 95 per cent and the incidence of encephalopathy
9 per cent; the latter was successfully managed by
protein restriction and/or lactulose therapy. The
actuarial survival rate for the whole group at 6 years
was 78 per cent, for those with Child-Pugh gradeA 88
per cent and for grade B 67 per cent. Small-lumen
mesocaval interposition shunting achieves portal
decompression, preserves hepatopetal flow, has a
low incidence of shunt thrombosis, prevents recur-
rent variceal bleeding and is not associated with
significant postoperative encephalopathy.
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PAPER DISCUSSION
The place of surgical operations in the treatment
of portal hypertension has become much more
circumscribed. For the most part, initial treat-
ment, both emergency and elective, is non-
surgical and involves a direct attack on the
varices, either sclerotherapy or banding. Balloon
tamponade and vasoactive drugs represent ad-
juvant treatment only. Surgery is used when
sclerotherapy or banding fails. Because of the
post-operative incidence of hepatic failure and
encephalopathy, end-to-side portacaval shunt
was abandoned in favour of operations aimed
to maintain prograde portal flow and hepatic
perfusion, e.g. distal splenorenal shunt, small-
diameter side-to-side portacaval shunts, etc The
value of maintaining hepatic perfusion remains
largely theoretical. The operation of mesocaval
interposition shunt had the advantage of techni-
cal simplicity. However, although the initial
results seemed good, long-term outcome was
not so optimistic in terms of rebleeding and
encephalopathy. Graft thrombosis was common.414 HPB INTERNATIONAL
The authors of this paper report a 5-year study
on 57 patients, using a polytetrafluoroethylene
(PTFE), small-diameter graft between the super-
ior mesenteric vein and the inferior cava. These
operations were carried out when sclerotherapy
had failed, failure being defined as two recur-
rences of bleeding from the oesophageal varices
or one recurrence from gastric varices. The
reported results seem good, with only 3 deaths
(5%) in the post-operative period, and only 2
recurrences of haemorrhage in the immediate
post-operative period and one recurrent later
bleed in the second year after operation. The
incidence of encephalopathy was reported as 9
per cent, and was managed successfully by
protein restriction and/or lactulose treatement.
The cumulative patency rate of the shunt was 95
per cent. Therewas a 75 per cent actuarial survival
rate at 6 years.
The patients were extensively investigated
before, and after, operation. The operative tech-
niques were standard apart from the use of a
PTFE graft. The patients were put on to heparin
initially intravenously and later subcutaneously,
to maintain a clotting level of twice normal.
Significant reduction in portal pressure was
achieved with shunt diameters of 10 and 12 milli-
metres. Prograde hepatic flow was preserved for
at least 3 years. Chronic encephalopathy did not
feature after shunting, but detailed description of
the results of pre- and post-operative tests for
encephalopathy were not provided.
The main criticism of the paper is that the
study was restricted to patients who had good
liver function, mainly Child-Pugh grade A and
B. In the experience of most clinicians in this
field, the majority of patients belong to the
Child-Pugh grade C. How did the authors treat
those in Child-Pugh grade C? Moreover, the
authors do not describe how they assessed the
severity of haemorrhage preceding these opera-
tions. Were these severe haemorrhages or mild,
but repeated, bleeds? There is good evidence that
the incidence of hepatic failure and encephalophy
after any type of shunt is remarkably low in
patients who have good liver function and who
have not bled severely.
There is no doubt that the interposition
mesocaval shunt is the easiest of all shunts to
perform. The shunt can be easily taken down if,
and when, liver transplant has to be undertaken.
The authors have an extensive experience in this
field, and have contributed significantly to the
surgical literature. However, since the early days
of end-to-side portacaval shunt, the tale has
always been the same. The first reports of a new
treatment have been most encouraging. The
initial studies have been undertaken in a small
number of highly-selected patients by an en-
thusiastic dedictated group. Only when the new
treatment has been undertaken in larger num-
bers, in a less selected group of patients, and
reported by a variety of groups, has pessimism
set in.
The use of PTFE graft for mesocaval inter-
position, therefore, is a useful technique for the
surgeon to keep at the back of his mind, for it is a
simple technique when the superior mesenteric
vein and the inferior vena cava are both patent.
The results of this paper apply only to a small
proportion of patients with bleeding oesophageal
varices, and it has notbeen proved that the results
are better than other forms of shunt. The authors
are invited to undertake a randomised control
trial comparing this technique with other estab-
lished procedures.
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